Vaccination in dogs and cats: choosing useful protection from the litter to adult life

1. Know the target and the outcome expected

A vaccine prepares an immune response against one or more specific agents. Its main benefit may be prevention of serious disease, reduction of clinical signs or limitation of particular consequences of infection. These outcomes are different. A correctly vaccinated cat may still develop respiratory signs without this demonstrating that all its vaccines are ineffective. Protection against one pathogen does not cover every possible cause of coughing, diarrhoea or deaths in a litter.

In breeding populations, vaccination belongs within a wider prevention plan: considered introductions, separation of sick animals, cleaning, equipment management and litter monitoring. It does not immediately make a contaminated environment safe and does not treat an animal already ill. The vaccination record documents procedures, but interpreting protection also requires the animal’s age, product, dates and circumstances. The single word vaccinated cannot describe all those factors. Asking which disease a product targets is more useful than counting the number of names on its label.

2. The immunity gap and vaccine options for young puppies

Antibodies received from the dam, mainly through colostrum, help protect puppies and kittens initially. They then decline from different starting levels and at different rates. Two young animals from the same litter may therefore respond differently to the same vaccination. A healthy dam or an observed suckling episode does not establish that every newborn received enough antibodies. Early management and each individual’s condition remain important.

A vulnerable period can occur when maternal antibodies no longer provide sufficient protection against disease but still interfere with the vaccine response. This is an important reason to repeat initial vaccinations rather than assume that the first one was sufficient. Conversely, deliberately waiting until all maternal antibodies are presumed absent leaves the young animal exposed during a vulnerable stage. Neither weaning date nor a puppy’s robust appearance can calculate this window individually. The plan should explain how protection is being pursued despite that uncertainty.

The immunity gap: a variable window, not a fixed age

This window of susceptibility is often called the immunity gap. The concentration that interferes with a vaccine response may be lower than that needed to protect against infection. Its timing depends on the pathogen, maternal transfer and vaccine; littermates need not reach it together. A previous case in a kennel makes this uncertainty especially relevant. Read the dedicated article on puppy and kitten immunity, colostrum and the immunity gap.

Compare vaccine characteristics, not brand names

Products differ in their components, minimum authorised age, ability to induce immunity in the presence of maternal antibodies, onset and duration of protection. Modified live viral vaccines, inactivated products and newer technologies are not interchangeable. A puppy-labelled product is not automatically suitable at every early age; a high-titre formulation does not mean administering a larger amount. The veterinarian selects the exact authorised product and plans the rest of the primary course. [1]

An example with specific evidence: Nobivac DP Plus

Nobivac DP Plus (MSD Animal Health/Intervet) combines distemper protection with the live recombinant parvovirus strain 630a. The European product information permits use from four weeks of age; early use is particularly discussed where infection risk is high. It states an onset of immunity of three days for parvovirus and seven days for distemper, with an eight-week duration. These are product-specific claims, not immediate protection or a complete puppy programme. Maternal parvovirus antibodies do not interfere with the product’s efficacy under its authorised conditions, whereas moderate to high maternal distemper antibodies can reduce distemper efficacy. Routine core vaccination must still follow. This dog product must not be extrapolated to kittens. [6]

Pearce and colleagues describe the development and experimental studies behind this parvovirus approach. Several authors are affiliated with MSD. These data support a particular option; they do not establish universal superiority over every alternative or guarantee control of a contaminated kennel. Product selection should use the current local product information, availability and clinical assessment. [7]

3. In dogs, match vaccine components to actual risk

Protection against canine distemper, adenovirus-associated infectious hepatitis and parvovirus forms the canine viral foundation. Other choices depend on geography and contact patterns. Leptospirosis is not relevant only to dogs that hunt or swim: assess local exposure and suitable vaccine coverage. WSAVA’s 2024 recommendations consider it core where disease occurs and appropriate vaccines are available. [1] A dog’s usual walking routine should therefore be discussed rather than using one outdoor activity as the sole criterion.

For group-associated respiratory disease, boarding, gatherings, breeding contacts and previous outbreaks matter. Vaccines targeting Bordetella or parainfluenza do not protect against every agent involved in kennel cough. Rabies also has public-health and travel implications; check official requirements for the particular circumstances. Selecting the product with the most components, or copying a timetable from another country, is not sufficient reasoning. The programme should state which protections are intended and what future changes in exposure would trigger review.

4. In cats, distinguish panleukopenia, respiratory disease and FeLV

The feline foundation includes panleukopenia and protection against feline herpesvirus and calicivirus. Their effects are not identical: respiratory vaccines do not remove every risk of disease, latency or carriage. Indoor cats may have indirect exposures or a future lifestyle change. Assessment cannot therefore be reduced to the single question of whether a cat currently goes outdoors. Introductions, boarding and the health of other cats in the household help define the context.

Feline leukaemia virus, or FeLV, is different from FIV. Age, introductions and contact with potentially exposed cats guide the decision. In affected regions, recent recommendations give particular importance to FeLV protection in young cats; anticipated future exposure should be considered. [1] Infection testing is interpreted separately from vaccination. FeLV vaccination does not treat established infection or protect against FIV. Chlamydia vaccination is discussed for particular indications rather than added automatically for every cat. An increased number of vaccine components is not, by itself, proof of a better individual plan.

5. Young animals need a programme followed through to completion

The initial series aims, among other things, to achieve a response when maternal antibody interference has become sufficiently low. It should not be stopped simply because a puppy has left the breeder or a kitten stays indoors. Each appointment has a purpose. The number of previous injections cannot be interpreted without knowing the ages at administration and the products involved. Handover at adoption should make the remaining plan explicit.

Completion of the viral primary series from sixteen weeks and revaccination from twenty-six weeks, approximately six months, are general WSAVA 2024 landmarks intended to reduce maternal-antibody-related failures. [1] They are not a complete timetable or a prescription for every vaccine: higher-risk circumstances, product information and individual assessment can alter the plan. The veterinarian should provide written next steps, including those after adoption. Do not improvise neonatal vaccination or catch-up from an old chart. Clarify any uncertainty in the record rather than assuming that a healthy appearance proves completion.

6. Reduce exposure without unnecessarily eliminating learning

Protection develops according to the response and the product’s properties; it is not acquired at the moment the animal leaves the consultation room. During this period, limit highly contaminated environments, contact with sick or unknown-status animals and shared equipment that has not been cleaned. An outbreak in a breeding group is different from a stable household. Vaccination does not replace immediate management of the exposure itself or the need to examine a sick young animal.

For puppies, reducing infectious risk does not mean removing all social and environmental learning. Selected contact with healthy animals and controlled settings can be planned with the veterinary team. Decisions depend on local pathogen circulation and the young animal’s likely protection. Within a litter, keep individual observations: appetite, weight, stools and activity can reveal a problem before every animal is affected. If the local situation changes, revise the exposure plan instead of relying on advice given under different circumstances.